RELATED PARTIES

6 Months Ended

Jun. 30, 2019

Related Party Transactions [Abstract]

Related Party Transactions

RELATED PARTIES

The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture and its diagnostic information services joint ventures, which are accounted for under the equity method of accounting. During both the three months ended June 30, 2019 and 2018, the Company recognized net revenues of $9 million associated with diagnostic information services provided to its equity method investees. During both the six months ended June 30, 2019 and 2018, the Company recognized net revenues of $18 million associated with such services. As of June 30, 2019 and December 31, 2018, there was $4 million and $3 million, respectively, of accounts receivable from equity method investees related to such services. During the three and six months ended June 30, 2019, the Company recognized net revenues of $2 million and $5 million, respectively, associated with diagnostic information services provided to a noncontrolling interest partner in a joint venture. As of June 30, 2019, there was $2 million of accounts receivable from the noncontrolling interest partner related to such services.

During both the three months ended June 30, 2019 and 2018, the Company recognized income of $4 million associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. During both the six months ended June 30, 2019 and 2018, the Company recognized income of $8 million associated with the performance of such services classified within selling, general and administrative expenses. As of both June 30, 2019 and December 31, 2018, there was $3 million of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of both June 30, 2019 and December 31, 2018 included $1 million due to equity method investees.